An integrative characterization of recurrent molecular aberrations in glioblastoma genomes

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in adults. Decades of investigations and the recent effort of the Cancer Genome Atlas (TCGA) project have mapped many molecular alterations in GBM cells. Alterations on DNAs may dysregulate gene expressions and drive malignancy of tumors. It is thus important to uncover causal and statistical dependency between ‘effector’ molecular aberrations and ‘target’ gene expressions in GBMs. A rich collection of prior studies attempted to combine copy number variation (CNV) and mRNA expression data. However, systematic methods to integrate multiple types of cancer genomic data—gene mutations, single nucleotide polymorphisms, CNVs, DNA methylations, mRNA and microRNA expressions and clinical information—are relatively scarce. We proposed an algorithm to build ‘association modules’ linking effector molecular aberrations and target gene expressions and applied the module-finding algorithm to the integrated TCGA GBM data sets. The inferred association modules were validated by six tests using external information and datasets of central nervous system tumors: (i) indication of prognostic effects among patients; (ii) coherence of target gene expressions; (iii) retention of effector–target associations in external data sets; (iv) recurrence of effector molecular aberrations in GBM; (v) functional enrichment of target genes; and (vi) co-citations between effectors and targets. Modules associated with well-known molecular aberrations of GBM—such as chromosome 7 amplifications, chromosome 10 deletions, EGFR and NF1 mutations—passed the majority of the validation tests. Furthermore, several modules associated with less well-reported molecular aberrations—such as chromosome 11 CNVs, CD40, PLXNB1 and GSTM1 methylations, and mir-21 expressions—were also validated by external information. In particular, modules constituting trans-acting effects with chromosome 11 CNVs and cis-acting effects with chromosome 10 CNVs manifested strong negative and positive associations with survival times in brain tumors. By aligning the information of association modules with the established GBM subclasses based on transcription or methylation levels, we found each subclass possessed multiple concurrent molecular aberrations. Furthermore, the joint molecular characteristics derived from 16 association modules had prognostic power not explained away by the strong biomarker of CpG island methylator phenotypes. Functional and survival analyses indicated that immune/inflammatory responses and epithelial-mesenchymal transitions were among the most important determining processes of prognosis. Finally, we demonstrated that certain molecular aberrations uniquely recurred in GBM but were relatively rare in non-GBM glioma cells. These results justify the utility of an integrative analysis on cancer genomes and provide testable characterizations of driver aberration events in GBM.

[1]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[2]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[3]  Dejan Juric,et al.  Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. , 2005, Cancer research.

[4]  I. Yang,et al.  Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma , 2010, Journal of Clinical Neuroscience.

[5]  J. Castle,et al.  An integrative genomics approach to infer causal associations between gene expression and disease , 2005, Nature Genetics.

[6]  D. Cox Regression Models and Life-Tables , 1972 .

[7]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[8]  I. Jonassen,et al.  Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation , 2009, Proceedings of the National Academy of Sciences.

[9]  E. Sen,et al.  TNFα regulates the localization of CD40 in lipid rafts of glioma cells , 2012, Molecular Biology Reports.

[10]  Nir Friedman,et al.  Bayesian Network Classifiers , 1997, Machine Learning.

[11]  Roberta Spinelli,et al.  A computational procedure to identify significant overlap of differentially expressed and genomic imbalanced regions in cancer datasets† , 2009, Nucleic acids research.

[12]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[13]  D. Valle,et al.  Online Mendelian Inheritance In Man (OMIM) , 2000, Human mutation.

[14]  K. Aldape,et al.  Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. , 2002, Cancer research.

[15]  D. Pe’er,et al.  Identifying regulatory mechanisms using individual variation reveals key role for chromatin modification , 2006, Proceedings of the National Academy of Sciences.

[16]  T. Jaakkola,et al.  Validation and refinement of gene-regulatory pathways on a network of physical interactions , 2005, Genome Biology.

[17]  N. Ahn,et al.  Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells , 2009, Oncogene.

[18]  D. Pe’er,et al.  Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data , 2003, Nature Genetics.

[19]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[20]  R. Simon,et al.  Controlling the number of false discoveries: application to high-dimensional genomic data , 2004 .

[21]  Christopher M. Jackson,et al.  Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment , 2011, Clinical & developmental immunology.

[22]  Susan M. Chang,et al.  Inherited variation in immune genes and pathways and glioblastoma risk , 2010, Carcinogenesis.

[23]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[24]  C. Bult,et al.  Functional annotation of a full-length mouse cDNA collection , 2001, Nature.

[25]  Alexander E. Kel,et al.  TRANSFAC®: transcriptional regulation, from patterns to profiles , 2003, Nucleic Acids Res..

[26]  Glutathione S-transferase M1, T1, and P1 polymorphisms and risk of glioma: a meta-analysis , 2013, Molecular Biology Reports.

[27]  C. Brennan,et al.  Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.

[28]  D. Gomez-Nicola,et al.  Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System , 2011, Clinical Medicine Insights. Oncology.

[29]  James B. Uney,et al.  Axotomy-Induced miR-21 Promotes Axon Growth in Adult Dorsal Root Ganglion Neurons , 2011, PloS one.

[30]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[31]  D.,et al.  Regression Models and Life-Tables , 2022 .

[32]  Ralph Weissleder,et al.  MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. , 2007, Cancer research.

[33]  Zhen-hua Hu,et al.  CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma , 2010, Journal of Neuroimmunology.

[34]  G. Hong,et al.  Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L , 2011, Journal of Neuroinflammation.

[35]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[36]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[37]  Stefano Ferrero,et al.  Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile , 2008, Molecular Cancer.

[38]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Pe’er,et al.  An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.

[40]  Juan Liu,et al.  A novel computational framework for simultaneous integration of multiple types of genomic data to identify microRNA-gene regulatory modules , 2011, Bioinform..

[41]  Chen-Hsiang Yeang,et al.  An integrated analysis of molecular aberrations in NCI-60 cell lines , 2010, BMC Bioinformatics.

[42]  C. Sander,et al.  Automated Network Analysis Identifies Core Pathways in Glioblastoma , 2010, PloS one.

[43]  Ülkü Öner,et al.  The importance of genomic copy number changes in the prognosis of glioblastoma multiforme , 2003, Neurosurgical Review.

[44]  Chen-Hsiang Yeang,et al.  Deciphering causal and statistical relations of molecular aberrations and gene expressions in NCI-60 cell lines , 2011, BMC Systems Biology.

[45]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[46]  A. Zwinderman,et al.  Statistical Applications in Genetics and Molecular Biology Quantifying the Association between Gene Expressions and DNA-Markers by Penalized Canonical Correlation Analysis , 2011 .

[47]  G. Hong,et al.  Nucleic Acids Research , 2015, Nucleic Acids Research.

[48]  K. Kelsey,et al.  Population-based study of glutathione S-transferase mu gene deletion in adult glioma cases and controls. , 1997, Carcinogenesis.

[49]  Sampsa Hautaniemi,et al.  Comparative analysis of algorithms for integration of copy number and expression data , 2012, Nature Methods.

[50]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[51]  Lincoln Stein,et al.  Reactome: a knowledgebase of biological pathways , 2004, Nucleic Acids Res..

[52]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[53]  Rainer Breitling,et al.  Expression Quantitative Trait Loci Are Highly Sensitive to Cellular Differentiation State , 2009, PLoS genetics.

[54]  Rainer Spang,et al.  Non-transcriptional pathway features reconstructed from secondary effects of RNA interference , 2005, Bioinform..

[55]  Jeremy C. McIntyre,et al.  Axon growth and guidance genes identify nascent, immature, and mature olfactory sensory neurons , 2010, Journal of neuroscience research.

[56]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[57]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Matthew A. Hibbs,et al.  Finding function: evaluation methods for functional genomic data , 2006, BMC Genomics.

[59]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[61]  Torbjörn E. M. Nordling,et al.  Network modeling of the transcriptional effects of copy number aberrations in glioblastoma , 2011, Molecular systems biology.

[62]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[63]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[64]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[65]  Adam A. Margolin,et al.  Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.

[66]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[67]  M. Prados,et al.  Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade , 1998, Genes, chromosomes & cancer.